Lonza boosts biopharma in south China
Print Edition
Swiss-based third-party biopharma research and development service provider Lonza is expanding its operations in southern Guangdong Province to add a new drug product 鈥渇ill and finish鈥 manufacturing line.
The leading contract development and manufacturing organization is stepping up local capacity as domestic biopharma enters a new stage and the number of innovative therapeutics rise quickly.
Biopharma is at the core of China鈥檚 fast-growing healthcare market in line with booming research and development in recent years.
Qianzhan Industry Research Institute estimated China鈥檚 biopharma industry will surpass 500 billion yuan (US$732 billion) in value by 2025, with an annual growth between 10 percent and 15 percent.
The newly-unveiled Guangzhou facility, which began operations in the second quarter, will enhance Lonza鈥檚 production capacity for both clinical and commercial production stages.
Installation of the new production line is expected to be completed in 2022 and will create more than 150 new jobs at the Guangzhou site.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
